Results 101 to 110 of about 63,889 (276)

Monitoring patients treated with anti-TNF- biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies

, 2007
Objectives. Infliximab is an anti-tumour necrosis factor-alpha (TNF-alpha) mousehuman IgG1/k antibody used to treat patients with rheumatoid arthritis (RA) and other inflammatory diseases.
Svenson, M., Geborek, P, Bendtzen, K., Saxne, Tore, Svenson, M, Geborek, P., Saxne, T, Bendtzen, K   +7 more
core   +1 more source

The ‘Cross‐Trust’ Histopathology Multidisciplinary Team: Report of meeting outputs and impact on paediatric inflammatory bowel disease management in a UK tertiary centre

JPGN Reports, EarlyView.
Abstract Objectives To evaluate the outputs and clinical impact of a Cross‐Trust Histopathology Multidisciplinary Team (MDT) created to support diagnostic clarification and management of complex paediatric inflammatory bowel disease (IBD) cases, particularly during transition to adult services.
Valeria Dipasquale, Alenka J. Brooks, Marta Cohen, Jonathan Bury, Akshay Kapoor, Priya Narula   +5 more
wiley   +1 more source

Infliximab to treat Crohn’s disease: an update

, 2011
M Cottone, V CriscuoliBiomedical Department of Internal and Specialist Medicine, Division of Medicine, Villa Sofia-V Cervello Hospital, Palermo University, Palermo, ItalyAbstract: Crohn’s disease (CD) is a chronic inflammatory disease of the ...
Criscuoli V, Cottone M
core  

INFLIXIMAB FOR REFRACTORY ULCERATIVE PROCTITIS

, 2010
International audienceBackground: Efficacy of infliximab in treating ulcerative proctitis is unknown. Aim: To evaluate clinical, biological and endoscopic efficacy of infliximab therapy in refractory proctitis. Methods: The charts of 420 patients treated
Bouguen, Guillaume, Siproudhis, Laurent, Flourie, Bernard, Roblin, Xavier, Hebuterne, Xavier, Feier, Laura, Nancey, Stéphane, Bretagne, Jean-François, Bourreille, Arnaud, Filippi, Jérôme, Peyrin-Biroulet, Laurent, Bigard, Marc-André   +11 more
core   +1 more source

Proactive therapeutic drug monitoring of infliximab leads to treatment durability in paediatric Crohn's disease: A single‐centre Australian experience

JPGN Reports, EarlyView.
Abstract Objectives To evaluate the durability and predictors of loss of response of infliximab (IFX) over 2 years in paediatric Crohn's disease (CD) utilizing a proactive therapeutic drug monitoring (TDM) strategy. Methods A retrospective, single‐centre cohort study was conducted at The Children's Hospital at Westmead (CHW), Australia, from January ...
Cher Wei Chuah, Jessica Eldredge, Annabel Magoffin, Edward Vincent O'Loughlin, Calvin Joomann Park, Juliana Puppi, Susan Siew, Michael Stormon, Kunal Thacker, Shoma Dutt   +9 more
wiley   +1 more source

Outcomes of adalimumab biosimilar nonmedical switches in children and young adults with inflammatory bowel disease

JPGN Reports, EarlyView.
Abstract Objectives Adalimumab biosimilars are as safe and effective compared to the originator. Adult patients with inflammatory bowel disease (IBD) who switched to a biosimilar have comparable outcomes, but pediatric data are limited. This study evaluates clinical outcomes of children and young adults with IBD following a nonmedical, insurance‐driven
Daniel Himelstein, Megan McNicol, Mahmoud Abdel‐Rasoul, Brendan M. Boyle, Hilary K. Michel, Ross Maltz   +5 more
wiley   +1 more source

Improvement of psychological status after infliximab treatment in patients with newly diagnosed Crohn’s disease

, 2018
Maochen Zhang,* Tianyu Zhang,* Liwen Hong, Chen Zhang, Jie Zhou, Rong Fan, Lei Wang, Zhengting Wang, Bin Xu, Jie Zhong Department of Gastroenterology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic ...
Hong L, Zhang T, Xu B, Zhang M, Zhang C, Zhong J, Fan R, Wang Z, Zhou J, Wang L   +9 more
core  

A joint transdisciplinary approach for paediatric inflammatory bowel disease: Integrating nursing, dietetic and psychological support

JPGN Reports, EarlyView.
Abstract Paediatric inflammatory bowel disease (pIBD) is a long‐term, immune‐mediated condition characterised by fluctuating gastrointestinal symptoms, nutritional risk and psychosocial difficulties. Although multidisciplinary team (MDT) support is considered the gold standard, there is considerable variation in how it is delivered, and it remains ...
King‐Chi Yau, Laura Tesser, Kay Crook
wiley   +1 more source

Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation

, 2007
OBJECTIVES: Correlation of serum trough infliximab levels and antibodies to infliximab (anti-infliximab) with clinical response in ankylosing spondylitis. METHODS: In accordance with the international ASsessment in Ankylosing Spondylitis (ASAS) consensus
de Vries, Mirjam K., Aarden, Lucien A., van Denderen, J. Christiaan, Dijkmans, Ben A. C., van der Horst-Bruinsma, Irene E., de Vrieze, Henk, Stapel, Steven O., Wolbink, Gerrit Jan   +7 more
core   +1 more source

Knowledge and practice regarding eosinophilic gastrointestinal disorders other than eosinophilic esophagitis among pediatric gastroenterologists of the Latin American Society for Pediatric Gastroenterology, Hepatology, and Nutrition

JPGN Reports, EarlyView.
Abstract Objective Evaluating clinical practices in the management of non‐esophageal eosinophilic gastrointestinal disorders (non‐EoE EGIDs) among pediatric gastroenterologists in Latin America. Methods A cross‐sectional descriptive study was conducted using a survey distributed via the REDCap platform.
Sofia Paz, Michelle Higuera Carrillo, Alonso Rafael Echavez Agudelo, Mário Cesar Vieira, Juan Pablo Riveros López, Natali González Rozó, Gustavo Javier Tagliaferro, Fabiola Sánchez Hernández, Catalina Ortiz Piedrahita, Wilson Daza Carreño, Ailim Margarita Carias Domínguez, José Fernando Vera Chamorro, Sabine Krüger Truppel, Maximiliano Fernández Rivas, César Augusto Moreno Serrano, Pablo Torres Córdova, Carlos Marcelo Timossi, Pablo Vásquez   +17 more
wiley   +1 more source